Company / SG&A Expense
ENDRA Life Sciences Inc. SG&A Expense History
FY2017-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$5.0M
FY2020
5-year range
$2.8M / $5.0M
FY2017-FY2020
Trend
+33.3%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $3M to $5M over the past 2 years.
Based on SEC 10-K filings.
$5M in FY2020 with a 3-year CAGR of +22.1%.
Increased from $3M to $5M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +22.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +22.1%, indicating consistent growth.
- In FY2020, sg&a expense increased 33.3% year-over-year.
Company context
Key Data Points
- Altman Z-Score -7.14 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | $5.0M | +33.3% |
| FY2019 | $3.8M | +36.4% |
| FY2018 | $2.8M | +0.0% |
| FY2017 | $2.8M | - |
As of FY2020 · SEC 10-K · Updated Jun 28, 2026